It is a new FTI consulting white paper title, co-writer with Kei-Sign. The essence is below.
In October 2023, ICER issued a special assessment in 2024 in 2024 with the aim of affecting the CMS drug price negotiations for two direct-interaction oral anticoagulants (doacs) selected in the first round of the Inflation Reduction Act (IRA) Price Dialogue: ELIQUIS® (APIXABAN) and Xarelto® (RivArylto® (RivArylto® (Rivaroxaban). In our evaluation, ICER’s approach is suffering from six major boundaries:
- The ICER rely on the same value as the years of life (EVLY) received the framework, which does not
Completely consider the improvement in sickness of new remedies. - Iceer evaluated treatment benefits from a narrow approach, ignoring the comprehensive value
to society. - ICER individually brought up value ELIQUIS® and Xarelto® value not taken into account
Patients and payment paid limited attention to IRA special population subgroups. - The ICER evaluated the treatment price based on the same signal despite doacs
Demonstration of health benefits for many patient populations
Signal. - Iceer failed to include better patient facilities and also how
The convenience can help reduce health inequalities. - The ICER considered a narrow evidence basis, ignoring the real world evidence studies
The real world treatment can inform the value.
These methodical intervals highlight the need for more inclusive and multi -faceted
Patient-centered care, social values and better aligns
The same objective determined by IRA.
You can read full white paper Here,
